Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.02.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Jeries Kort und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Rese…. Hauptthemen laut MEDLINE: Melphalan, Multiple Myeloma, Neoplasm, Residual, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH. Electronic address: jerieskort@gmail.co…
- Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH.
- Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH.
- Department of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH.
- Case Western Reserve University, Department of Population and Quantitative Health Sciences, Cleveland, OH.
Zitieren
APA
Kort, J., Naleid, N., Oley, F., Ignatz-Hoover, J., Margevicius, S., Fu, P., Malek, E., & Cooper, B. (2025). Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.02.004
Vancouver
Kort J, Naleid N, Oley F, Ignatz-Hoover J, Margevicius S, Fu P, et al. Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.02.004
BibTeX
@article{Kort2025,
author = {Kort, Jeries and Naleid, Nikolas and Oley, Frank and Ignatz-Hoover, James and Margevicius, Seunghee and Fu, Pingfu and Malek, Ehsan and Cooper, Brenda},
title = {Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.02.004}
}
EUVIMED